Ardelyx

Ardelyx

Biotechnology, Ardenwood BLVD Ste 200, Waltham, , 94555, Massachusetts, 34175, United States, 51-200 Employees

ardelyx.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 51********

Who is ARDELYX

Ardelyx is a publicly traded biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medic...

Read More

map
  • 34175 Ardenwood BLVD Ste 200, Waltham, Massachusetts, 94555, United States Headquarters: 34175 Ardenwood BLVD Ste 200, Waltham, Massachusetts, 94555, United States
  • 2007 Date Founded: 2007
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 32 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from ARDELYX

Ardelyx Org Chart and Mapping

Employees

Jennifer Swanson-Ms

Area Business Director (Nephrology)

Maggie Marcoux

Sr. Director, Sec Reporting, Technical Accounting & Sox

Nina Chen

Regulatory Operation Specialist

Susan Rodriguez

Chief Commercial Officer

Noah Martinez

Area Business Director

Ashley Mayer

Gastroenterology Area Business Director

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Ardelyx

Answer: Ardelyx's headquarters are located at Ardenwood BLVD Ste 200, Waltham, , 94555, Massachusetts, 34175, United States

Answer: Ardelyx's phone number is 51********

Answer: Ardelyx's official website is https://ardelyx.com

Answer: Ardelyx's revenue is $1 Million to $5 Million

Answer: Ardelyx's SIC: 2834

Answer: Ardelyx's NAICS: 32

Answer: Ardelyx has 51-200 employees

Answer: Ardelyx is in Biotechnology

Answer: Ardelyx contact info: Phone number: 51******** Website: https://ardelyx.com

Answer: Ardelyx is a publicly traded biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyxs first approved product, IBSRELA (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH (tenapanor), a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis who have had an inadequate response or intolerance to phosphate binder therapy, which has completed three successful Phase 3 trials and an additional two Phase 4 open label trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access